Altimmune Reports Q1 2026 Results, $535M Cash, and Advances Pemvidutide Clinical Trials

summarizeSummary

Altimmune announced its Q1 2026 financial results, reporting a strong cash position of $535 million and providing positive updates on its pemvidutide clinical development, including a planned Phase 3 MASH trial.

check_boxKey Events

• Strong Cash Position Reported

  The company reported $332 million in cash, cash equivalents, and short-term investments as of March 31, 2026, further increasing to $535 million by April 30, 2026, following recent public offerings.

• Pemvidutide Phase 3 MASH Trial Planned

  Altimmune plans to initiate its global PERFORMA Phase 3 MASH trial for pemvidutide in the second half of 2026, with 52-week data anticipated in 2029. The study protocol has been finalized and submitted to the FDA.

• Upcoming Clinical Data Readouts

  Topline data from the RECLAIM Phase 2 AUD trial is expected in Q3 2026, and enrollment completion for the RESTORE Phase 2 ALD trial is also anticipated in Q3 2026.

• Q1 2026 Financial Performance

  The company reported a net loss of $22.6 million, or $0.18 per share, for the first quarter of 2026, compared to a net loss of $19.6 million, or $0.26 per share, in the same period of 2025.

auto_awesomeAnalysis

Altimmune reported its first quarter 2026 financial results, highlighting a significantly strengthened balance sheet with $535 million in cash as of April 30, 2026. This substantial cash position, largely due to recent public offerings, provides a long runway for the company's clinical programs. The company also provided positive updates on its lead drug pemvidutide, including plans to initiate a Phase 3 MASH trial in the second half of 2026 and upcoming data readouts for its AUD and ALD trials, reinforcing its development pipeline.